Analysts Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) PT at $22.83

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $22.83.

NMRA has been the subject of a number of research reports. HC Wainwright began coverage on shares of Neumora Therapeutics in a report on Tuesday, October 1st. They issued a “buy” rating and a $30.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Neumora Therapeutics in a research note on Friday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $29.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday, September 4th. Finally, Mizuho initiated coverage on Neumora Therapeutics in a report on Monday, July 8th. They issued an “outperform” rating and a $20.00 target price on the stock.

Neumora Therapeutics Stock Down 14.8 %

NASDAQ:NMRA opened at $14.05 on Friday. Neumora Therapeutics has a 52-week low of $8.33 and a 52-week high of $21.00. The stock’s 50 day moving average price is $12.79 and its 200 day moving average price is $11.33. The company has a market capitalization of $2.24 billion and a PE ratio of -5.49.

Neumora Therapeutics (NASDAQ:NMRA) last announced its earnings results on Tuesday, August 6th. The company reported ($0.37) EPS for the quarter, meeting analysts’ consensus estimates of ($0.37). As a group, sell-side analysts anticipate that Neumora Therapeutics will post -1.48 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Joshua Pinto sold 28,496 shares of the stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $11.63, for a total value of $331,408.48. Following the completion of the transaction, the chief financial officer now owns 210,469 shares in the company, valued at $2,447,754.47. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, insider Robert A. Lenz sold 30,788 shares of the firm’s stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total value of $363,606.28. Following the completion of the transaction, the insider now owns 339,205 shares in the company, valued at $4,006,011.05. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Joshua Pinto sold 28,496 shares of the business’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $11.63, for a total transaction of $331,408.48. Following the completion of the sale, the chief financial officer now owns 210,469 shares in the company, valued at $2,447,754.47. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 110,538 shares of company stock worth $1,390,513. Corporate insiders own 26.40% of the company’s stock.

Hedge Funds Weigh In On Neumora Therapeutics

Hedge funds have recently bought and sold shares of the stock. Auour Investments LLC purchased a new stake in Neumora Therapeutics in the 1st quarter valued at about $1,445,000. Callan Capital LLC acquired a new stake in shares of Neumora Therapeutics in the first quarter valued at about $2,819,000. Nan Fung Group Holdings Ltd purchased a new stake in shares of Neumora Therapeutics during the first quarter valued at approximately $871,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Neumora Therapeutics during the first quarter worth $10,354,000. Finally, Baker BROS. Advisors LP acquired a new position in shares of Neumora Therapeutics during the first quarter worth $8,715,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.